Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin

Thrombosis and Haemostasis

Volumn 85, Issue 3, 2001, Pages 435-440

  Sheth, S B ^a   DiCicco, R A ^a   Hursting, M J ^a   Montague, T ^a   Jorkasky, D K ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Argatroban; Direct thrombin inhibitors; International normalized ratio; Warfarin

Indexed keywords

ARGATROBAN; BLOOD CLOTTING FACTOR 10; THROMBOPLASTIN; WARFARIN;

ADULT; ANALYZER; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; GINGIVA BLEEDING; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL STANDARD UNIT; MALE; MONOTHERAPY; NORMAL HUMAN; PARALLEL DESIGN; PARTIAL THROMBOPLASTIN TIME; PREDICTION; PRIORITY JOURNAL; PURPURA; RANDOMIZED CONTROLLED TRIAL;

EID: 0035082406     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615601     Document Type: Article

References (24)

1. Argatroban provides effective and safe anticoagulation in patients with heparin-induced thrombocytopenia: A prospective, historical controlled study
2. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
3. Antithrombin agents as anticoagulants and antithrombotics: Implications in drug development
4. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters
5. Anticoagulant effects of Hirulog, a novel thrombin inhibitor, in patients with coronary artery disease
6. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors
7. Anticoagulant activity of Hirulog™, a direct thrombin inhibitor, in humans
8. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration
9. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina: A multicenter trial
10. Phase one study of synthetic antithrombin agent (MD-805) single and multiple administration studies
11. Comparative pharmacology of site directed antithrombin agents. Implication in drug development
12. Standardization of the prothrombin time for monitoring orally administered anticoagulant therapy with use of the international normalized ratio system
13. Synthetic selective inhibitors of thrombin
14. Monitoring warfarin during concurrent argatroban therapy in healthy volunteers: Use of the International Normalized Ratio versus factor X by amidolytic assay
15. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction
16. The International Normalized Ratio during concurrent warfarin and argatroban anticoagulation: Differential contributions of each agent and effects of the choice of thromboplastin used
17. Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy
18. Factor X values as a means to assess the extent of oral anticoagulation in patients receiving antithrombin drugs
19. Mechanism of action and monitoring of anticoagulants
20. PTs, PRs, ISIs, and INRs: A primer on prothrombin time reporting. Part II: Limitations of INR reporting
21. ASHP therapeutic position statement on the use of the International Normalized Ratio system to monitor oral anticoagulant therapy
22. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors
23. Hirudin in acute myocardial infarction: Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial